This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and epidemiology data, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The approved drugs in the opioid-induced constipation (OIC) space predominantly target opioid receptors, with the exception of Amitiza, a type-2 chloride channel activator. All of the marketed drugs are administered via the oral route, with one product also being available in a subcutaneous formulation.
• There are only two industry-sponsored drugs in active clinical development for OIC, with one drug each in Phase II and Phase III. Therapies in active clinical development for OIC target opioid receptors and guanylyl cyclase c receptor. These therapies are administered via the oral route.
• The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 17.3%, and the average probability a drug advances from Phase III is 65.7%. Drugs, on average, take 10.0 years from Phase I to approval, compared to 9.9 years in the overall gastroenterology (non inflammatory bowel disease) space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for OIC have been in the late phases of development, with 60% of trials in Phase III–IV, and 40% in Phase I–II.
• Clinical trial activity in the OIC space is dominated by completed trials. Progenics Pharmaceuticals has the highest number of completed clinical trials for OIC, with 13 trials.
• Progenics Pharmaceuticals leads the industry sponsors with the highest overall number of clinical trials for OIC, followed by Pfizer.